Psychemedics PMD

$2.67 -0.05 (-1.84%)

Valuation

Market cap: 15,738,000
Revenue TTM: $22,100,000
Net income TTM: $-4,150,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: -18.78%
Debt to equity: 0.00

Trading

Volume: 113,600
Avg volume: 35,668
Day's range: $2.46 – $2.77
Shares out: 5,894,000
Stochastic %K: 51%
Beta: 0.65
Analysts: Strong Buy
Price target: —

Price

Company profile

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 800 527 7424
Website: https://www.psychemedics.com
Address: 5220 Spring Valley Road, Suite 230, Dallas, United States

Latest news

No headlines yet.

Stocktwits

iamyahweh Jan 9, 6:04 PM

$PMD 🔜🪐🚀🚀🚀🚀🚀

0 replies

Murph1968 Jan 7, 10:41 PM

$PMD Another year of zero interest in my investment here. Another year of no resolution from HHS. Yet, I find myself topping off my investment here. I’m prepared to wait, as one of these bills could gain some traction yet this year.

0 replies

prismmarketview Dec 10, 5:23 PM

PRISM Mid-Day Movers: Healthcare and Emerging Psychedelics are Leading Today’s Index’s Psychemedics ( $PMD) doubles on a low-float squeeze as volume triples its norm, while Enveric Biosciences ( $ENVB) rips into the low teens on a new U.S. patent allowance for its neuroplastogenic pipeline, turning both names into high‑beta sentiment gauges for speculative biotech. Other Notable Movers: iBio Inc. ( $IBIO) up 46% Biodexa Pharmaceuticals PLC ( $BDRX) up 24% Polestar ( $PSNY) down 23% https://prismmarketview.com/prism-mid-day-movers-healthcare-and-emerging-psychedelics-are-leading-todays-indexs/

0 replies

prismmarketview Dec 8, 5:23 PM

PRISM Mid-Day Movers: Emerging Weight Loss and Healthcare are kicking off this weeks movement Structure Therapeutics ( $GPCR) rips over 100% on positive topline ACCESS data for oral GLP‑1 aleniglipron, while Psychemedics ( $PMD) doubles off 52‑week lows on thin OTC buying, making both names standout movers in today’s emerging weight loss and healthcare trade. Other Notable Movers: Immutep Limited ( $IMMP) up 50% Ibio, Inc. ( $IBIO) up 47% TFF Pharmaceuticals ( $TFFP) down 60% https://prismmarketview.com/prism-mid-day-movers-emerging-weight-loss-and-healthcare-are-kicking-off-this-weeks-movement/

0 replies

HyperBulls Apr 22, 1:33 PM

$INBS @HorseShaq19 It is likely that we will see a company acquisition or merger as you mentioned. Potential is hugeee $ABT Abbott Laboratories (ABT) Revenue: ~$40.1 billion (total), diagnostics segment ~$10 billion (including drug testing) Test Types: Urine, saliva (via Alere brand) $DGX Quest Diagnostics (DGX) Revenue: ~$9.3 billion (drug testing services ~20-25%) Test Types: Urine, blood, hair, saliva $OSUR OraSure Technologies (OSUR) Revenue: ~$400 million Test Types: Saliva (oral fluid test kits) $PMD Psychemedics Corporation (PMD) Revenue: ~$50 million Test Types: Hair Intelligent Bio Solutions (INBS) Revenue: ~$0.61 million Test Types: Fingerprint sweat (non-invasive)

0 replies

Esau815 Apr 2, 1:18 PM

$PMD My bottom line assessment is that this was a multi step process: (1) was to reduce expenses to stem the cash bleed, (2) to wait out the trucking industry malaise and reap the benefits of its turnaround and (3) hope for good news from HHS regarding hair testing registry. Step 1 was within their control and I don't know how much more they can cut. Two thousand square foot office space? What's next? Sharing cell phones? Let's assume Hulligan did a good job. Step 2 and Step 3 is basically we have to wait and see. JBHT said that they foresee a turnaround. The wild card of HHS? Not expecting much but if that comes through--and it's anti Labor and Trump hates anything associated with Labor--that its' got a shot. At this point? You'll get more information from JBHT than you will PMDI regarding PMDI.

0 replies

Esau815 Mar 7, 4:52 AM

$PMD This is a step by step story and will take a while to get there. Step 1 should happen in Q1 2025. At that point, the professional expenses to do the deal will have been completed and the cost saves that Hullinger has been working on for 15 months should start to follow the bottom line. Revenues a complete unknown. But if revenues even hold steady they should get to cash flow break even pretty quickly. Step 2 is when the trucking business picks up. JBHT is rather cautious about their growth but they mentioned adding 800 to 1,000 trucks to their fleet during the last CC. Step 3: is if HHS and then DOT takes steps to register and possibly require hair testing. Though the meeting is in May it's likely that will be kicked down the road a bit.

2 replies

Murph1968 Feb 26, 4:54 PM

$PMD Took some $2.29’s today. Feeling anything below $2.35 is a great purchase long term.

0 replies